Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398769 | 0.88 | CA2 (0.46) | SNCACA2MMP1MMP2MMP9 | |
| SCHEMBL18322761 | 0.86 | SNCA (0.43) | SNCACA2MMP1MMP2MMP9 | |
| SCHEMBL3429467 | 0.85 | SNCA (0.42) | SNCAALDH1A1 | |
| SCHEMBL7057723 | 0.83 | BCHE (0.46) | SNCAALDH1A1 | |
| SCHEMBL27829874 | 0.83 | SNCA (0.42) | SNCAALDH1A1 | |
| SCHEMBL2061458 | 0.82 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL27848279 | 0.81 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL19717778 | 0.81 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL12330698 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MMP1MMP2MMP9MMP8 | |
| SCHEMBL8605151 | 0.79 | HDAC3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | SNCA 4004/4885ALDH1A1 411/4885CA2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.